Full-Time
Join us to build the future of drug discovery
Posted on 6/21/2024
Vevo Therapeutics
11-50 employees
In vivo drug discovery data services
No salary listed
San Bruno, CA, USA
Hybrid position requiring in-office presence.
Hybrid position requiring in-office presence.
Hybrid position requiring in-office presence.
 Biology & Biotech (6) |
|---|
| , , , , , |
- Single-cell bioinformatics on large atlas datasets
- Machine learning applied to genomics data and cheminformatics
- High throughput synthetic lethal oncology genomics screens and subsequent target validation of individual genes
- Junior Scientists with tissue culture, single-cell sample preparation, laboratory automation using robotics, and biochemical assays for target validation and mechanistic investigation
- Medicinal chemistry, particularly in small molecule oncology
Vevo Therapeutics provides pharmaceutical companies with high-resolution data to accelerate drug discovery using its Mosaic platform and AI models. The platform works by pooling cells from many different patients into a single living organism and using single-cell RNA profiling to see how drugs affect gene expression across diverse populations in one experiment. Unlike competitors that test drugs on isolated cells in tubes, Vevo captures how drugs behave within living tissue to better predict real-world results. The company's goal is to make in vivo drug discovery scalable and precise to find better treatments for a wider range of patients.
Company Size
11-50
Company Stage
Seed
Total Funding
$12M
Headquarters
San Francisco, California
Founded
2022
Simplify's Take
What believers are saying
- $12M seed from General Catalyst and Wing funds thousands of Mosaic experiments.
- Tahoe-100M open-sourced with Arc Institute fosters pharma collaborations.
- Parse GigaLab partnership generated Tahoe-100M atlas in five weeks.
What critics are saying
- Rebranding to Tahoe Bio erodes Vevo brand equity in 3-6 months.
- Open-sourcing Tahoe-100M lets Recursion train superior AI models.
- Parse GigaLab overload halts Mosaic operations within 6-12 months.
What makes Vevo Therapeutics unique
- Mosaic platform scales in vivo single-cell data across hundreds of patients per experiment.
- Tahoe-100M dataset profiles 100M cells from 1,200 drugs and 50 tumor models.
- AI models trained on in vivo atlas uncover targets missed by in vitro assays.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Vevo Therapeutics who can refer or advise you
Benefits
Unlimited Paid Time Off
Health Insurance
Dental Insurance
Vision Insurance
Company News
Vevo Therapeutics has officially released the Tahoe-100M, described as the world's largest single-cell dataset, in collaboration with the Arc Institute.
Vevo Therapeutics partners with the Parse Biosciences GigaLab to generate 100M cell atlas for AI powered drug discovery.
Vevo Therapeutics, an SF-based biotechnology company, launched today with a $12M seed round led by General Catalyst and Wing Venture Capital using its Mosaic in vivo drug discovery platform and next-generation AI models to uncover better drugs for more patients.
Vevo Therapeutics, a biotechnology company using its Mosaic in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients, launched today with an oversubscribed and upsized $12M seed financing round.